Date	Period	Revenue/Estimate	Earnings Call
--	2025/Q1	-- / 7.510B	--
--	2024/Q4	-- / 7.681B	--
Oct 30, 2024	2024/Q3	8.012B / 8.007B	--
Jul 31, 2024	2024/Q2	7.884B / 7.493B	--
May 1, 2024	2024/Q1	7.363B / 7.060B	--

DatePeriodRevenue/EstimateEarnings Call

--2025/Q1-- / 7.510B--

--2024/Q4-- / 7.681B--

Oct 30, 20242024/Q38.012B / 8.007B--

Jul 31, 20242024/Q27.884B / 7.493B--

May 1, 20242024/Q17.363B / 7.060B--

Unlock Free Earnings Estimates

Open Account

6-K: Gsk on track to deliver 2024 outlooks with further good progress made in r&d

Oct 30, 2024 11:27 ET

6-K: Gsk Delivers Continued Strong Performance and Upgrades 2024 Guidance

Jul 31, 2024 12:31 ET

6-K: Gsk Makes a Strong Start to 2024 with Improving Outlook for the Year

May 1, 2024 12:34 ET

GlaxoSmithKline | 6-K: Glaxosmithkline 2023 Annual Report on Form 20-F

Mar 5, 2024 13:13 ET

Symbol Mini Chart % Chg

Unlock the Full List

Analysis

Updated: Dec 31, 2024

Hold

No Data